Herein we present an overview of the infrastructure of producing 211At radiopharmaceuticals, from target to radiolabeled product including chemical strategies to overcome hurdles for advancement into clinical trials with 211At.Background Long noncoding RNAs could serve as a candidate target for prostate cancer (PCa) diagnosis and treatment. The…[Read more]